Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis

Multiple Sclerosis

Volumn 22, Issue 7, 2016, Pages 921-925

  Signoriello, E ^a   Lanzillo, R ^b   Brescia Morra, V ^b   Di Iorio, G ^a   Fratta, M ^a   Carotenuto, A ^b   Lus, G ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Biomarkers; multiple sclerosis; Natalizumab

Indexed keywords

NATALIZUMAB; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD EXAMINATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PREDICTION; RETROSPECTIVE STUDY; RISK FACTOR; BLOOD CELL COUNT; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE DURATION; RECURRENT DISEASE; RELAPSE; BLOOD; CHEMICALLY INDUCED; IMMUNOLOGY; LEUKOCYTE COUNT; PREDICTIVE VALUE; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; LYMPHOCYTOSIS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATALIZUMAB; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84973455035     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515604381     Document Type: Article

References (12)

1. Comi G,. Treatment of multiple sclerosis: role of natalizumab. Neurol Sci 2009; 30: S155-158.
2. Frisullo G, Iorio R, Plantone D, et al. CD4+T-bet+,CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment. Mult Scler 2011; 17: 556-566.
3. Neumann F, Zohren F, Haas R,. The role of Natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther 2009; 9: 1099-1106.
4. Zohren F, Toutzaris D, Klärner V, et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34 hematopoietic progenitor cells in humans. Blood 2008; 111: 3893-3895.
5. Mattascio M, Muraro P, Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis. Neurology 2015; 84: 1473-1482.
6. Lublin FD, Reingold SC,. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
7. Skarica M, Eckstein C, Whartenby KA, et al. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol 2011; 235: 70-76.
8. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
9. Sangalli F, Moiola L,. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci 2011; 31: 299-302.
10. Zanotti C, Chiarini M, Serana F, et al. Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients. Clin Immunol 2012, 145: 19-26.
11. Koudriavtseva T,. Long-term follow up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with Natalizumab. Clin Expl Immunol 2014; 176: 320-326.
12. Rossi S, Motta C, Centonze D,. A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Mult Scler 2013; 19: 59.